How Cancers Outsmart the Immune System and the Therapies Fighting Back
A sweeping 2025 review maps every major immune evasion strategy tumors use and the next-gen therapies designed to defeat them.
Summary
Cancer cells deploy a sophisticated arsenal to escape immune destruction: they suppress T cells with cytokines like TGF-β and IL-10, recruit immunosuppressive Tregs and MDSCs, hijack checkpoint pathways (PD-1/PD-L1, CTLA-4, LAG-3, TIM-3, TIGIT), and acidify the tumor microenvironment with lactate to paralyze immune cells. Metabolic byproducts such as ammonia further kill effector T cells via lysosomal damage. This comprehensive 2025 review from Central South University synthesizes these mechanisms alongside emerging countermeasures—bispecific antibodies, oncolytic viruses, nanotechnology-based immunotherapies, CAR-T cells, and cancer vaccines—arguing that personalized, multi-omics-guided combination strategies are essential to overcome therapeutic resistance and improve patient survival.
Detailed Summary
**Why This Matters** Immune evasion is the central reason most cancers are difficult to treat and why even promising immunotherapies fail in many patients. Understanding the full spectrum of evasion tactics is a prerequisite for designing therapies that can sustainably restore anti-tumor immunity.
**What Was Studied** This is a comprehensive narrative review published in *Signal Transduction and Targeted Therapy* (July 2025) by Tufail, Jiang, and Li from Xiangya Hospital, Central South University. The authors synthesized the current literature on four interlocking evasion domains: tumor-induced immune suppression, immune checkpoint regulation, tumor microenvironment (TME) modulation, and antigen presentation defects, alongside an analysis of key signaling pathways and emerging therapeutic strategies.
**Key Mechanisms Identified** Tumors secrete immunosuppressive cytokines—TGF-β, IL-10, and VEGF—that collectively blunt T cell and NK cell activity, block dendritic cell maturation, and expand regulatory T cells (Tregs). MDSCs further suppress immunity by depleting arginine and producing reactive oxygen and nitrogen species. Metabolic reprogramming is a particularly underappreciated driver: aerobic glycolysis floods the TME with lactate, lowering pH to levels that directly impair T cell signaling (reducing cytotoxic activity by up to 50%), repolarize macrophages to the immunosuppressive M2 phenotype, and hamper dendritic cell priming. Ammonia, generated through glutaminolysis in proliferating T cells, causes lysosomal alkalization and mitochondrial damage, triggering a novel form of T cell death. On the checkpoint front, PD-1/PD-L1 and CTLA-4 remain the dominant pathways, but LAG-3, TIM-3, and TIGIT are emerging co-inhibitory receptors that drive T cell exhaustion and resistance to single-agent checkpoint blockade. Dual or triple checkpoint inhibition—including bispecific molecules like tebotelimab (PD-1×LAG-3)—is showing early clinical promise.
**Therapeutic Implications** The review highlights that no single intervention suffices. Combination strategies targeting metabolic acidification (e.g., bicarbonate supplementation, carbonic anhydrase IX inhibition, proton pump inhibitors) alongside checkpoint blockade restored immune cell infiltration and improved survival in preclinical models. Bispecific antibodies, oncolytic viruses, and nanotechnology-driven delivery systems represent the next frontier, potentially enabling simultaneous multi-target engagement. Multi-omics profiling of individual tumors is emphasized as critical for matching patients to the right combination regimen.
**Caveats** As a review, no new experimental data are generated; conclusions depend on the quality and breadth of cited studies. Many promising findings (bicarbonate supplementation, ammonia-mediated T cell death, novel checkpoint combos) remain in preclinical or early-phase stages, and clinical translation timelines are uncertain.
Key Findings
- Lactate from tumor glycolysis lowers TME pH, reducing CTL cytotoxic activity by up to 50% and impairing macrophage and NK cell function.
- Ammonia from glutaminolysis triggers lysosomal alkalization and mitochondrial damage, inducing a novel T cell death pathway.
- LAG-3, TIM-3, and TIGIT co-expression with PD-1 drives T cell exhaustion and resistance to single-agent checkpoint inhibitors.
- Neutralizing acidic TME with bicarbonate or proton pump inhibitors restored immune infiltration and boosted checkpoint blockade efficacy in mouse models.
- Bispecific antibodies (e.g., tebotelimab targeting PD-1 and LAG-3) show early clinical responses across multiple solid tumor types.
Methodology
This is a comprehensive narrative review, not an original clinical or preclinical study. The authors synthesized peer-reviewed literature on cancer immune evasion mechanisms, signaling pathways, and therapeutic strategies. No original datasets, patient cohorts, or experimental protocols were generated by the review authors themselves.
Study Limitations
As a narrative review, it is subject to selection bias in the literature cited and does not include meta-analytic rigor. Most mechanistic findings on lactate, ammonia, and novel checkpoints derive from preclinical models, and clinical validation in large randomized trials is largely pending. The breadth of topics covered means some areas (e.g., epigenetic regulation, tumor heterogeneity) are addressed at a high level rather than in granular mechanistic detail.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.